cancer

Meet some of the finalists of this year's Best Places to Work in Academia survey. 

A male hormone-blocker currently used to treat prostate cancer may also benefit breast cancer patients.

In contrast to yesterday’s news about the success of an HPV vaccine program in Australia, an Indian trial of the vaccine is stoking unfounded fear among the public and exposing some questionable ethical standards.

Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.

A former postdoctoral researcher at St. Jude Children’s Research Hospital fudged images published in two papers, one of which has since been retracted.

An HPV vaccination program in Australia appears to have resulted in a drop in cervical lesions among young women.

A snapshot of the most highly ranked articles in immunology and related areas, from Faculty of 1000.

Proteins and nanoparticles that talk in order to more efficiently locate and treat tumors could reduce collateral damage to healthy tissues.

Fourteen years after closure, an asbestos plant is still damaging DNA

Ovarian tumor cells use cellular movement proteins to penetrate protective cell layers surrounding new target tissues during metastasis.

The US government releases an updated list of potential carcinogens that includes seven new chemicals and biological agents.

The Scientist covered some of the events that made this year's festival memorable.

New compounds are showing promise in targeting subpopulations of cancer stem cells.

A study commissioned by the World Health Organization suggests that electromagnetic fields given off by cell phones may cause brain cancer. 

Looking back, looking ahead

How to follow stem cells transplanted into living tissue.

Decades of vaccine research have expanded our understanding of the immune system and are yielding novel disease-fighting tactics.

The challenges of crystallizing membrane proteins—and how they’re being overcome.

Researchers identify a pathway that allows leukemia to evade a common cancer treatment -- and develop a way to block it

Chronic users of acetaminophen (Tylenol) have a higher risk of developing blood cancer, according to a study published this week in the Journal of Clinical Oncology.